Business · Markets · 51 mins ago
Olympus Shares Fall After FDA Warning Letter Following Six Facility Inspections
Olympus shares fell sharply after the US Food and Drug Administration issued the company a warning letter.
Olympus is a Japanese medical-device maker.
The FDA had previously conducted inspections at six Olympus facilities.
The warning letter followed those inspections, though the reason for the agency's action is not stated.
The share decline was Olympus's steepest since April 2025.
The stock move shows the market response to the FDA action, but no further steps are specified.
Olympus shares fell sharply after the company said it received a US Food and Drug Administration warning letter about medical-device quality control.
The FDA issued the letter after inspections at six Olympus facilities, Bloomberg reported.
On October 14, the shares fell 16.50% to 1,697 yen, their lowest level since July 1, according to Nikkei.
Bloomberg said the drop was the shares’ steepest since April 2025.
- Who
- Olympus Corp., a Japanese medical device maker.
- What
- The FDA issued Olympus a warning letter after inspections at six facilities, and Olympus shares fell sharply.
- When
- Olympus said it received the letter on October 13, 2026; its shares fell on October 14.
- Where
- The inspections were at six Olympus facilities. The locations are not stated.
- Why
- The letter concerned quality control for medical devices and followed FDA inspections.
This story does not have two clearly opposing sides.
The FDA conducted inspections at six Olympus facilities.
Olympus said it received an FDA warning letter concerning medical-device quality control.
Olympus shares fell 16.50% to 1,697 yen, according to Nikkei.
- Facilities inspected
- Six
- Share price change
- Down 16.50%
- Share price
- 1,697 yen
- Warning letter received
- October 13, 2026